MARKET

ENTX

ENTX

Entera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.14
-0.05
-0.96%
After Hours: 4.900 -0.24 -4.67% 18:50 07/27 EDT
OPEN
5.20
PREV CLOSE
5.19
HIGH
5.20
LOW
4.960
VOLUME
131.35K
TURNOVER
--
52 WEEK HIGH
10.16
52 WEEK LOW
1.000
MARKET CAP
122.21M
P/E (TTM)
-6.3060
1D
5D
1M
3M
1Y
5Y
Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 Index.
Benzinga · 07/04 14:16
Thinking about buying stock in Bridgeline Digital, Seelos Therapeutics, Vistagen Therapeutics, BioLineRx, or Entera Bio?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLIN, SEEL, VTGN, BLRX, and ENTX.
PR Newswire - PRF · 07/01 12:30
Entera Bio Shares Spike Higher Following Co. Press Release Highlighting Upcoming Jun. 30 Conference Call To Discuss 'Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis'
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results from its successfully completed Phase 2
Benzinga · 06/28 19:16
Entera Bio Stock Could More Than Double From Here, Says Analyst
In the biotech space, big announcements often precede big share price movements; both were on tap for Entera Bio (ENTX) on Wednesday. Entera shares took off after the company provided an update from the placebo-controlled, double blind Phase 2 trial of EB6...
TipRanks · 06/25 22:23
Entera (ENTX) Up on Positive Results From Osteoporosis Drug
Zacks.com · 06/24 16:38
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23)
Benzinga · 06/24 12:12
--B. Riley Raises Entera Bio's PT to $14 from $9 After Encouraging Clinical Results of EB613 Study, Keeps Buy Rating
MT Newswires · 06/24 09:19
45 Biggest Movers From Yesterday
Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613.
Benzinga · 06/24 09:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENTX. Analyze the recent business situations of Entera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENTX stock price target is 12.00 with a high estimate of 14.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 12
Institutional Holdings: 4.11M
% Owned: 17.30%
Shares Outstanding: 23.78M
TypeInstitutionsShares
Increased
3
99.36K
New
5
72.77K
Decreased
0
0
Sold Out
2
43.71K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.04%
Pharmaceuticals & Medical Research
-0.18%
Key Executives
Chairman/Independent Director
Gerald Lieberman
Chief Executive Officer/Director
Spiros Jamas
Chief Financial Officer
Dana Yaacov-Garbeli
Corporate Executive
Phillip Schwartz
Chief Operating Officer
Hillel Galitzer
Other
Ramesh Ratan
Other
Arthur Santora
Director
Zeev Bronfeld
Director
Sean Ellis
Director
Yonatan Malca
Director
Ron Mayron
Independent Director
Faith Charles
Independent Director
Gerald Ostrov
Independent Director
Miranda Toledano
No Data
About ENTX
Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism, osteoporosis and bone healing.

Webull offers kinds of Entera Bio Ltd stock information, including NASDAQ:ENTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENTX stock methods without spending real money on the virtual paper trading platform.